Farzaneh Darbeheshti, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 9 | 2024 | 3785 | 0.970 |
Why?
|
| Gene Regulatory Networks | 3 | 2021 | 1748 | 0.860 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2021 | 190 | 0.720 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2021 | 136 | 0.670 |
Why?
|
| RNA, Untranslated | 1 | 2021 | 453 | 0.590 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 365 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2024 | 8611 | 0.510 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 455 | 0.480 |
Why?
|
| RNA, Messenger | 5 | 2023 | 12768 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 18071 | 0.420 |
Why?
|
| Communicable Diseases | 1 | 2021 | 874 | 0.400 |
Why?
|
| Models, Genetic | 1 | 2020 | 3449 | 0.340 |
Why?
|
| Influenza, Human | 1 | 2021 | 1539 | 0.330 |
Why?
|
| DNA | 1 | 2022 | 7202 | 0.310 |
Why?
|
| Polymerase Chain Reaction | 3 | 2024 | 6069 | 0.240 |
Why?
|
| Melanoma | 2 | 2024 | 5719 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9373 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 5849 | 0.200 |
Why?
|
| Immunogenetics | 1 | 2022 | 62 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 429 | 0.170 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2021 | 168 | 0.170 |
Why?
|
| Mannose-Binding Lectin | 1 | 2021 | 146 | 0.170 |
Why?
|
| Orthomyxoviridae | 1 | 2021 | 147 | 0.170 |
Why?
|
| Genes, X-Linked | 1 | 2020 | 129 | 0.160 |
Why?
|
| Oligonucleotides | 1 | 2022 | 561 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2023 | 23601 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2024 | 1102 | 0.160 |
Why?
|
| Iran | 2 | 2023 | 761 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 323 | 0.150 |
Why?
|
| Melanocytes | 1 | 2022 | 515 | 0.150 |
Why?
|
| Toll-Like Receptors | 1 | 2021 | 583 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 1742 | 0.140 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 800 | 0.140 |
Why?
|
| Neoplasms | 2 | 2024 | 22340 | 0.140 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 523 | 0.130 |
Why?
|
| Receptors, Virus | 1 | 2020 | 651 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 11499 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 1153 | 0.120 |
Why?
|
| Computational Biology | 3 | 2022 | 3559 | 0.120 |
Why?
|
| China | 1 | 2021 | 2385 | 0.120 |
Why?
|
| Humans | 21 | 2024 | 765968 | 0.110 |
Why?
|
| ROC Curve | 1 | 2021 | 3620 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2023 | 10429 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2423 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 6942 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3513 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22223 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1587 | 0.100 |
Why?
|
| Alleles | 2 | 2024 | 6897 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 3819 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 16047 | 0.090 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 21056 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 3655 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2017 | 3624 | 0.090 |
Why?
|
| Mutation | 3 | 2024 | 30198 | 0.080 |
Why?
|
| Prognosis | 4 | 2024 | 29922 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2021 | 3081 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 6832 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2021 | 3050 | 0.080 |
Why?
|
| Gene Expression | 1 | 2021 | 7584 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2023 | 3459 | 0.070 |
Why?
|
| Cell Line | 1 | 2021 | 15543 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 11206 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2022 | 12131 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9525 | 0.060 |
Why?
|
| Female | 9 | 2023 | 396112 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2021 | 4752 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2020 | 6610 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4900 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 9071 | 0.050 |
Why?
|
| Pregnancy | 1 | 2022 | 30260 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 385 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2020 | 752 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2024 | 2054 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 1624 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 2428 | 0.030 |
Why?
|
| Male | 3 | 2023 | 363698 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2024 | 3047 | 0.020 |
Why?
|
| Child | 1 | 2020 | 80564 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 2371 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2024 | 4424 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 74840 | 0.020 |
Why?
|
| Adult | 2 | 2023 | 223044 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 13024 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2022 | 17075 | 0.020 |
Why?
|
| Aged | 1 | 2023 | 171117 | 0.010 |
Why?
|
| Middle Aged | 1 | 2023 | 223009 | 0.000 |
Why?
|